Content about Genomics

March 28, 2013
Ethnicity, genomics and personalized medicine

For well over a century, the Statue of Liberty has invited the world to “Give us your tired, your poor, your huddled masses yearning to breathe free.” Now, thanks to stunning advances in the sequencing of the human genome and patient-specific genetic research, America’s healthcare system is extending another invitation to this nation’s complex polyglot population.

For well over a century, the Statue of Liberty has invited the world to “Give us your tired, your poor, your huddled masses yearning to breathe free.” Now, thanks to stunning advances in the sequencing of the human genome and patient-specific genetic research, America’s healthcare system is extending another invitation to this nation’s complex polyglot population: give us the rich diversity of your DNA.

March 26, 2013
The genomics revolution has begun in pharmacy

It’s often the case that those in the midst of revolutionary times don’t really see how fundamentally the world around them is changing until long after the changes have occurred. So let’s start by declaring that the revolution has begun: Genomic research will dramatically transform both the practice of pharmacy and the way patients are treated with medications for many diseases.

The sequencing of the human genome was a huge scientific breakthrough, and it’s spawning additional breakthroughs as genetic testing labs spring up and the cost of testing individual patients for their ability to metabolize a particular drug drops to affordable levels for health plan payers.

It’s often the case that those in the midst of revolutionary times don’t really see how fundamentally the world around them is changing until long after the changes have occurred. So let’s start by declaring that the revolution has begun: Genomic research will dramatically transform both the practice of pharmacy and the way patients are treated with medications for many diseases.

April 25, 2012
Reports: GSK calls $2.6 billion offer for Human Genome Sciences 'full and fair'

GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

Reuters reported that GSK's $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.

October 6, 2011
Speaker panel to discuss genomics in cancer care

Genomics has the potential to revolutionize the treatment of cancer and the drug industry, and the New York Pharma Forum is sponsoring a symposium on the subject in December.

NEW YORK — Genomics has the potential to revolutionize the treatment of cancer and the drug industry, and the New York Pharma Forum is sponsoring a symposium on the subject in December.

The symposium, titled "The Genomics Revolution: Cancer and Beyond," will feature a panel discussion with executives from drug makes like Bristol-Myers Squibb and Daiichi Sankyo, as well as experts from the Yale Cancer Center and PricewaterhouseCoopers.

April 25, 2011
Kerr expands beyond the counter

Expanding the role of pharmacy far beyond the counter has long been a hallmark of Kerr Drug’s business model, and the chain’s Kerr Community Health Center is one of the best examples. 


January 5, 2011
Researchers find link between heart attacks, Alzheimer’s

BOLOGNA, Italy — Data from a new study by scientists in Italy could help physicians calculate patients’ risks for Alzheimer’s disease and heart attacks. Researchers at the University of Bologna said they found a common genetic link between heart attacks and Alzheimer’s, according to results of a study published in the Journal of Alzheimer’s Disease.


June 6, 2010
Walgreens, CVS delay test kit sales as FDA signals tougher stance

Adopting a tougher and more interventionist tone with the U.S. drug and medical device market,...

May 19, 2010
Report: House panel led by Waxman now investigating genetic testing kits

Federal scrutiny over at-home genetic testing continues to snowball in the wake of an abortive...